Gastric cancer with peritoneal metastases: Efficiency of standard treatment methods

Table 2 Treatment methods of 200 intraperitoneally-disseminated gastric cancer patients

Treatment modality		n (%)
BSC	Total	105 (52.5)
	Only BSC	31 (29.5)
	Attempted or non-resectable palliative surgery + BSC	74 (70.5)
	Stage of peritoneal carcinomatosis according to JGCA
	P0 (Cyt+)	0
	P1	20 (19)
	P2	23 (21.9)
	P3	62 (59.1)
	PCI
	0 (Cyt+)	0
	1-6	31 (29.5)
	7-12	13 (12.4)
	13 +	60 (57.2)
	Unknown	1 (0.9)
Palliative chemotherapy	Total	51 (25.5)
	Only palliative chemotherapy	24 (47)
	Attempted or non-resectable palliative surgery + palliative chemotherapy	27 (53)
	Stage of peritoneal carcinomatosis according to JGCA
	P0 (Cyt+)	0
	P1	6 (11.8)
	P2	9 (17.6)
	P3	36 (70.6)
	PCI
	0 (Cyt+)	0
	1-6	9 (17.6)
	7-12	8 (15.7)
	13 +	32 (62.7)
	Unknown	2 (4)
	Chemotherapy regimen
	CF	19 (37.2)
	5-FU	11 (21.6)
	CAF	10 (19.6)
	XELOX	7 (13.7)
	ECF	3 (5.9)
	Tegafur	1 (2)
Palliative gastrectomy	Total	44 (22)
	Only palliative gastrectomy	40 (91)
	Palliative gastrectomy + palliative chemotherapy	4 (9)
	Stage of peritoneal carcinomatosis according to JGCA
	P0 (Cyt+)	4 (9.1)
	P1	20 (45.4)
	P2	8 (18.2)
	P3	12 (27.3)
	PCI
	0 (Cyt+)	4 (9.1)
	1-6	24 (54.5)
	7-12	4 (9.1)
	13 +	12 (27.3)
	Lymph node dissection
	D0, 1	35 (79.5)
	D1+, 2	9 (20.5)
	Completeness of cytoreduction score
	CC-0	9 (20.5)
	CC-1	19 (43.2)
	CC-2	16 (36.3)

JGCA: Japanese Gastric Cancer Association; PCI: Peritoneal cancer index; CC: Completeness of cytoreduction; BSC: Best supportive care.